Butibufen

Research use only, not for human use.

Butibufen (FF-106) is an orally active non-steroidal anti-inflammatory compound, a potential cyclooxygenase inhibitor with analgesic and antipyretic activity, and inhibits urea synthesis.Butibufen has been used in the study of rheumatic diseases.

Butibufen is an orally active non-steroidal compound. Butibufen shows analgesic and antipyretic properties. Butibufen can be used for the research of inflammation.

Butibufen (0.1 μM-0.1 M; 60 min) affects cell viability and cell attachment with a high dose.Butibufen (1 μM; 48 h) causes a 100% cell death after 48 h exposure.Butibufen (2 μM-1 mM; 6 h) affects synthesis of albumin in hepatocytes.Butibufen (0.2-0.4 mM; 6 h) impaires gluconeogenesis from lactate and significantly inhibited ureogenesis.Cell Viability Assay Cell Line:Hepatocytes from Sprague-Dawley male rats Concentration:0.1 μM-0.1 M Incubation Time:60 min Result:Showed no cell viability effects under the dose of 200 μM, but dose- and time-dependently affected cell viability with higher concentrations.

Butibufen (50 and 250 mg/kg; p.o. 8 and 3 h before sacrifice) affects acid phosphatase activity.Animal Model:Sprague-Dawley rats Dosage:50 and 250 mg/kg Administration:Oral gavage; 50 and 250 mg/kg; 8 and 3 h before sacrifice Result:Reduced acid phosphatase activity but showed no effect on the stabilization of lysosomal membrane.

——

Immunology/Inflammation

Lipoxygenase

Lipoxygenase

——

——

55837-18-8

220.31

C14H20O2

>98% (HPLC)

——

O=C(O)C(C1=CC=C(C=C1)CC(C)C)CC

——

(-20℃)

With Ice Pack

≥ 2 years